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Introduction
'Ecstasy' (3,4-methylenedioxymethamhetamine, MDMA) is widely used, with an estimated 10.5 to 25.8 million users globally (1) . In Australia, the highest prevalence is among those aged 20-29 years where nearly 10% report using ecstasy in the last year (2) . This consumption raises potential health concerns as the use of ecstasy appears to have longlasting impacts on serotonin function (3) . Data from animal studies, including among nonhuman primates, have indicated neurotoxic effects of MDMA on the serotonin 5-HT system at doses equivalent to those used by recreational ecstasy users (4) (5) . Potential serotonergic neurotoxicity has been implicated in depressed mood (6) (7) (8) . However, pre-existing mental health disorders in stimulant users (9) , environmental and genetic risk factors plus other demographic factors (e.g. unemployment, lower education) may also account for this association (10) (11) .
Sleep disruption may account for, or in part account for, the increased levels of depressive symptomology often observed in ecstasy users. Sleep disruption is a prevalent symptom of mood disorder (12) and included in many measures of depression and emotional distress (13) (14) (15) . It is also a potential consequence of ecstasy use due to the pharmaceutical properties of the drug (16) (17) or lifestyle factors associated with its use (18) . Data from animal studies has shown that even a single exposure of 15mg/kg MDMA in rats can produce increased wakefulness and motor activity evident to 28 days (19) with some impacts on sleep function still evident at 180 days in rats (20) . In a sample of social drug users, clinically important levels of sleep disturbance have been observed among ecstasy users after controlling for poly-drug use (21) . However, findings regarding the persistent impacts of ecstasy use on sleep patterns in humans are inconsistent, and indicate that sleep differences between users and non-users may be pre-existing or due to other drug use (22) .
Few ecologically valid studies of the relationship between ecstasy use and sleep disturbance have been conducted to investigate whether or not the data from the laboratory translates to external settings. Moreover, interpretation of these findings is complicated by (a) the exact constitution of 'ecstasy' consumed outside the laboratory, which may contain a range of other psychoactive substances in addition to MDMA, and (b), the co-use of alcohol and other drugs that also impact on sleep. The acute use of meth/amphetamine is expected to increase wakefulness and reduce the total amount of sleep, followed by a rebound period of extended sleep, and then a period of sleep disruption (23-24). Both cannabis and alcohol may initially appear to have sleep-inducing properties. However, tolerance develops to the sleep-inducing effect of cannabis (22) and alcohol increases the fragmentation of sleep, with alcohol withdrawal associated with considerable sleep disruption (24) . A recent study by Ogeil and colleagues considered this issue by controlling for poly-drug use (21), but did not examine the potentially important, differential impacts of different categories of drugs.
The aim of this study was to use prospective data from a representative, adult community cohort to examine the relationship between the ecstasy consumption and sleep problems, operationalised as the use of sleeping medications (pharmaceutical or other substances). To address the aforementioned limitations of former ecological studies these analyses will control for key factors, in particular, cannabis, meth/amphetamine hazardous/harmful use of alcohol and mood problems. Sleep disturbance is also associated with trauma and is one of the diagnostic features of post-traumatic stress disorder (12) so a measure of lifetime traumatic events was included too. Thus, the study will make a unique contribution in identifying whether or not the posited link between recreational use of ecstasy and depression is likely to be due to increased sleep problems.
Method

Sample
The "Personality and Total Health Through Life Project" (PATH) is a cohort study that assesses adult lifespan changes in wellbeing, mental health, personality and cognitive function. At recruitment, the cohorts were aged 20-24, 40-44 and 60-64 years with follow-up conducted every four years. The recruitment process has previously been described in detail answered the questions on the use of ecstasy at wave two) were included in analyses. (28) . At wave three, question 3 of the AUDIT was modified to reflect the Australian Guidelines in place at the time (29) : women were asked about consuming five or more standard drinks and men about consuming seven or more. Cannabis use was assessed using items from an existing survey and a two item screening test (30) (31) . Based on these questions participants were classified as either "never users", "not current users" (last used more than 12 months prior to interview or reported "don't currently use") or "infrequent users" (used in the last 12 months, once or twice per year to every 1-4 months"), ">monthly" (used in the last 12 months, once per month to "once a week or more"). Ecstasy use was classified into the same categories, as was meth/amphetamine except as noted above, at wave three data on frequency was not collected for some cases. Smoking tobacco was classified as "current", "former", "never" smokers. The presence of major or other depression was derived from the standard algorithm for the nine-item Brief Patient Health Questionnaire (BPHQ) (15) (e.g. "major depression": question 1a or b and five or more of items a-h are "more than half the days" or item i endorsed: "other depression" as per major depression except endorsing two to four items.) Response options refer to feelings over the last twoweeks and are: not at all, several days, more than half the days, nearly every day. The BPHQ gives a 'provisional' diagnosis: to make a formal diagnosis other causes must be ruled out such as bereavement, a history of manic episodes, physical illness, medications and drug use.
Measures
Lifetime trauma was assessed with ten items adapted from the National Survey of Mental Health and Wellbeing and including combat experience, life threatening accident, natural disaster, rape, sexual molestation, serious assault, torture (32) . Lifetime trauma was the sum of events prior to wave two, plus events between waves two and three.
Analysis
At baseline, socio-demographic and substance use variables were compared between groups (those who have never versus ever used ecstasy at wave two) using chi square analysis for lifetime trauma and socio-demographic variables that showed significant differences between users and non-users of ecstasy at wave two. The structure was specified with subject number as the repeated measure and wave the within subject variable. Cases with missing dependent variable or covariate data are excluded by GEE. The interaction of ecstasy and time was examined to explore whether differences in ecstasy use across waves was associated with differences in sleep. This interaction was not significant and is thus not reported in the results. Finally, logistic regression, with simultaneous entry of measures, was used to predict wave three sleeping medications from wave two data. (99.9%) provided ecstasy data (658, 33% ever used: 1319, 67% never used), of whom 239 (12.1%) used sleep medications. At both waves, of those who had ever used ecstasy, a greater proportion were male, only had high school education, were employed, had never been married, had higher trauma scores and a greater proportion used sleep medications. They also had a greater proportion reporting current tobacco, cannabis and meth/amphetamine use and were classified as hazardous alcohol consumers (Table 1) . Participants could record multiple types of sleeping medications or aids, with the most frequently reported at both waves being benzodiazepines (or other hypnotics), herbal remedies, and antihistamines (Table 2) . Notably, a greater percentage of ecstasy users reported the use of benzodiazepines at both waves, compared to non-ecstasy users. Finally, there were significant correlations between all types of substances used, in particular ecstasy and meth/amphetamine (Spearman's rho wave two .708: wave three .693) (online Appendix B). Table 2 here Table 3 shows the GEE model on the left hand side. The odds of using sleep medications was increased for females (odds ratio (OR) = 1.44 95% confidence interval (CI) 1.13, 1.84) and for those who were classified as having depression (OR = 1.88 95% CI 1.39, 2.53). Each major trauma increased the odds of sleeping medication use by 19% (95% CI 1.12, 1.26) . The association between >monthly ecstasy (versus never) (OR = 1.10) and sleep medication was not significant. Those who used meth/amphetamine >monthly versus never had increased odds of sleep medication use (OR = 3.03, 95% CI 1.30, 7.03). In addition, >monthly cannabis use (versus never) (OR = 1.78 95% CI 1.05, 3.01) was associated with an increased odds of using sleeping medications. Logistic regression of wave two data on wave three sleeping medication showed that none of the substance use variables were significant predictors, but that gender (OR = 1.37), depression (OR = 1.65) and trauma (OR = 1.17) remained significant predictors (Table 3 right hand side).
Table 3 here
Two sensitivity analyses were conducted. The first restricted sleep medications to 'pharmacist only' or prescription medications, defined as benzodiazepines (or other hypnotics), antihistamines, and analgesics combined with antihistamines. This analysis was conducted to determine whether the above findings were biased by the inclusion of nonspecific or less effective products. There were 85 (4.0%) people using these at wave two and 115 (5.8%) at wave three. In replicating the earlier analytic plan, ecstasy use was still not significantly related to the use of sleep medication. Meth/amphetamine produced similar results to those of the main analysis (>monthly OR = 4.18), with gender (female OR = 1.63) and depression (OR = 1.94) significantly increasing the odds of using sleep medications, while each additional trauma increased the odds by 24%. The second sensitivity analysis excluded participants with missing data on the frequency of meth/amphetamine use at wave three (Table 4 , right hand half). The results were similar to those in the main analysis.
Table 4 here
Discussion
Data from animal studies have shown that the use of MDMA ('ecstasy') disrupts sleep patterns over an extended period (19) . However, findings from human ecstasy users are equivocal with studies finding increases and decreases in sleep (16, 34) . Furthermore, data from naturalistic settings have typically recruited purposefully sampled groups or convenience samples and even where poly-drug use has been accounted for in analyses, the effects of different drug classes are not examined separately (21) . This study makes an important contribution through its employment of a general population sample to assess the relationship between the use of ecstasy and sleep problems, indexed as the use of sleeping medications (pharmaceutical or other substances) while controlling for other key factors.
Univariate statistics showed that ecstasy users reported greater rates of sleep medication use.
However, multivariate models found no increased odds of sleep medication use for ecstasy users compared to non-users, when their use of other drugs was accounted for. Use of meth/amphetamine or cannabis were associated with a greater likelihood of sleeping medication use in these models. These findings were largely replicated in a sensitivity analysis restricted to prescription or pharmacist only sleeping medications.
Poly-drug use is prevalent amongst ecstasy consumers (10) (11) 35) and is one of the limiting factors in translating data from animal models involving MDMA to human ecstasy users. In the present study, people who used meth/amphetamine monthly or more had three times the odds of using any sleeping medication and four times the odds of using a prescription or pharmacist only medication. Amphetamine-induced sleep disorder with insomnia in the acute phase and hypersomnia during withdrawal is well characterised (12) . However, after a few days of hypersomnia, insomnia is likely, continuing at least until 20 days (23). Given this disruption, the use of sleeping medications is unsurprising following the use of meth/amphetamine in either the immediate aftermath or to cope with persistent insomnia.
The absence of a significant relationship between ecstasy and sleeping medication use once other drug use was accounted for indicates that the higher rates of sleeping medication reported amongst ecstasy users in our community sample is attributable to the greater use of methamphetamines and/or cannabis also observed amongst this group. It is worth noting, however, that this is a statistical finding and does not rule out the possibility that (some) ecstasy users do take sleeping medications to address the effects of this drug. However, the use of other drugs that are more strongly associated with sleep medication use amongst this group means that it not possible to definitively identify which drug may lead to medication consumption. Further, the absence of a multivariate association between ecstasy use and sleep medication use is an important finding and contribution to the literature as it demonstrates the importance of measuring and controlling for poly-drug use. Inability to do so may lead to erroneous conclusions about sleeping problems amongst ecstasy users.
The use of sleeping medications was also associated with: being female, being categorised with depression and life-time traumatic events. Reasons for the higher prevalence of sleeping problems among women (36) is not clearly understood, but both lifespan and menstrual fluctuations in hormones levels have been implicated (37) . The relationship between sleep disturbance, traumatic events and mental health problems is complex, with insomnia associated with the risk of developing depression (38) ; pre-existing sleep disturbance being a risk factor for the development of mental health problems following traumatic events (39) and traumatic events disrupting sleep (40) . Thus, the triumvirate of non-substance use risk factors reported in the current study are consistent with the literature.
The consumption of sleeping medications was used as a proxy for sleep disturbance in this study. The BPHQ (which was included as a covariate in our models) contains two items pertaining to sleep ('Trouble falling or staying asleep, or sleeping too much' and 'Feeling tired or having little energy'). Thus, it is possible that the inclusion of the BPHQ as a measure of depression may mask some of the relationship between meth/amphetamine use, or indeed ecstasy use, and sleeping medications. A sensitivity analysis (results not shown) removing the BPHQ from the model marginally increased the odds ratio for meth/amphetamine but not for ecstasy, reinforcing the interpretation that the extent of sleep disruption for ecstasy users in this group was not severe.
There are a number of limitations associated with this study. First, sleep disruption was not directly assessed either with self-report measures or polysonography. However, even selfreported sleep data is not without criticisms (41) . Second, the temporal relationship between drug use and sleep medication cannot be guaranteed. The use of sleeping medications in the PATH study had a reference period of the last month and substance use data was collected for the last year. Thus, whilst it is likely that the latter was consumed first, the length of time between drug use and sleep medication use may vary. That is, it was monthly or more frequent use or that was associated with the use of sleeping medications, but it is unknown if this was during the acute phase or during a later period when sleep disruptions may persist.
Third, the purity and presents of adulterants in the ecstasy is unknown. Street 'ecstasy' may contain little or no MDMA and instead maybe a mixture of meth/amphetamine, ketamine and other substances (42) . Over the period 2003-2008, the purity of Australian drug seizures for this class of drugs remained relatively stable, although the proportion of ecstasy users in the ACT reporting 'high' purity declined (43) (44) . Thus, these findings may not generalise to settings with different purity formulations of ecstasy. Four, the missing frequency data on 258 meth/amphetamine users at wave three represent 43% of those using this substance. If all these cases were >monthly users, the magnitude of the OR would be reduced but still significant: if they were all infrequent users, this category would still not be significant (analysis not shown). Nevertheless, these shortcoming should not negate the importance of data collected from a representative community cohort in contrast to the previous overreliance on snowballing and purposive recruitment (18) .
Conclusion
Animal models show long-term disruption of sleep following exposure to MDMA. The present study is one of few to examine this relationship in a representative general community sample, and the first to account for concurrent use of other drugs associated with sleeping problems that are commonly consumed by ecstasy users. We found that ecstasy use was not associated with the use of sleeping medications when other drug use was accounted for. There was, however, a strong relationship between the use of meth/amphetamine and sleep medication. Future studies must measure and account for this association to avoid misinterpretation of the univariate link between ecstasy use and poor sleep. Gender female n (%) male n (%)
823 (56) 636 (44) 297 (44) Education high school n (%) post school n (%) tertiary n (%)
257 (18) 541 (37) 659 (45) 151 (23) 239 (36) 279 (42) χ 2 7.4 (2) p=.025
156 (12) 496 (38) 646 (50) 116 (18) 248 (38) 281 (44) χ 2 14.4 (2) p=.001
Employment full or part time n (%) want more work/unemployed n (%) not in the labour force n (%)
1259 (86) 68 (5) 132 (9) 587 (88) 43 (6) 39 (6) χ 2 8.6 (2) p=.012
2438 (88) 94 (3) 246 (9) 1179 (89) 71 (5) 77 (6) Cannabis never n (%) not current user n (%) infrequent user n (%) >monthly user n (%) 507 (35) 815 (56) 101 (7) 31 (2) 7 (1) 303 (46) 184 (27) 173 (26) χ 2 640.0 (3) p<.001
438 (33) 809 (62) 33 (3) 33 (3) 9 (1) 442 (67) 123 (19) 82 (13) χ 2 419.7 (3) p<.001
Meth/amphetamine never n (%) not current user n (%) infrequent user n (%) >monthly user n (%) unknown frequency n (%)
1338 (94) 80 (6) 1202 (91) 114 (9) 2 (<1) 1 (<1) 0 (0) 174 (27) 127 (19) 85 (13) 13 (2) 258 ( 
Antihistamines n (%) 17 (10) 12 (9) 30 (17) 7 (6) Antihistamines + Analgesics n (%) 7 (4) 1 (1) 4 (3) 7 (6) Benzodiazepines or other hypnotics a n (%) 28 (17) 38 (28) 30 (17) 31 (27) Cannabis &/or alcohol n (%)
Other analgesics n (%) 22 (13) Table 4 Sensitivity analyses a) for use of prescription or pharmacist only sleeping medications (left half of table n=2082) and b) excluding those with unknown frequency of meth/amphetamine use at wave three (right half n=2079). All p values <.001 except as marked Categories: alcohol (Hazardous use yes/no), tobacco (current, former, never), cannabis (> monthly, infrequent, former, never), ecstasy (> monthly, infrequent, former, never), meth/amphetamine (wave two: > monthly, infrequent, former, never) (wave three:frequency unknown, > monthly, infrequent, former, never)
